Falling Costs Make Genomics (and Their ETFs) More Attractive than Ever
December 09, 2020 at 11:18 AM EST
One of the most compelling elements in the genomics investment thesis is that costs are declining, making the next generation of healthcare solutions more accessible. That trend also benefits financial assets, such as the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG). Many of the...